SATURATE-MS

Treatment tested

• Natalizumab

  Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor

Other measures (6)

Key Inclusion Criteria: * Diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS) according to 2017 revised McDonald criteria * Initiation of treatment with SC NTZ according to summary of product characteristic (SmPC) and in accordance to national guidelines or * Continuing treatment with IV NTZ * Owns and be able to handle a smartphone Key Exclusion Criteria: * Participants with an acute MS relapse and/or a history of intravenous corticosteroid treatment within past six weeks * Any comorbidity resulting in an impairment to understand or successfully complete the study such as (but not restricted to) psychiatric comorbidities or dementia * Diagnosis of primary or secondary progressive MS * Additional immunosuppression except of natalizumab NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

The primary objective of this study is to better understand the pathophysiological background of end-of-dose symptoms (EOD) and thereby determine the percentage of participants who develop EOD under natalizumab (NTZ) as an example of interval therapy in MS and to detect specific changes through multimodal analyses, including radiological, blood and digital health measurements, that may be used as potential biomarkers in the future to map EOD.